Connection

Robert Stuart to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

This is a "connection" page, showing publications Robert Stuart has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
  1. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
    View in: PubMed
    Score: 0.155
  2. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011 Jun 02; 117(22):5941-52.
    View in: PubMed
    Score: 0.092
  3. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar 01; 17(5):1140-6.
    View in: PubMed
    Score: 0.090
  4. Autologous bone marrow transplantation for leukemia. Semin Oncol. 1993 Oct; 20(5 Suppl 6):40-54.
    View in: PubMed
    Score: 0.027
  5. Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. 1990; 26(6):397-402.
    View in: PubMed
    Score: 0.021
  6. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009 Dec; 37(12):1464-71.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.